Prescribing Paxlovid™ (nirmatrelvir and ritonavir) for COVID-19

Question Title

1. Please rate how we met the course objectives.

After completing this course:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19.	I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19. Strongly agree	I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19. Agree	I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19. Neutral	I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19. Disagree	I understand patient assessment and prescribing process requirements for community prescribing of Paxlovid™ for mild COVID-19. Strongly disagree
I can identify patients requiring referral and describe the referral process to ensure timely access to care.	I can identify patients requiring referral and describe the referral process to ensure timely access to care. Strongly agree	I can identify patients requiring referral and describe the referral process to ensure timely access to care. Agree	I can identify patients requiring referral and describe the referral process to ensure timely access to care. Neutral	I can identify patients requiring referral and describe the referral process to ensure timely access to care. Disagree	I can identify patients requiring referral and describe the referral process to ensure timely access to care. Strongly disagree
I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level.	I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level. Strongly agree	I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level. Agree	I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level. Neutral	I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level. Disagree	I can outline Saskatchewan guidance on drug interactions and how to manage at a community prescriber level. Strongly disagree
I can locate helpful resources and additional supports for Paxlovid™.	I can locate helpful resources and additional supports for Paxlovid™. Strongly agree	I can locate helpful resources and additional supports for Paxlovid™. Agree	I can locate helpful resources and additional supports for Paxlovid™. Neutral	I can locate helpful resources and additional supports for Paxlovid™. Disagree	I can locate helpful resources and additional supports for Paxlovid™. Strongly disagree
I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19.	I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19. Strongly agree	I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19. Agree	I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19. Neutral	I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19. Disagree	I can share experiences and insights from experts working in infectious disease and treatment of early COVID-19. Strongly disagree

Question Title

2. Evaluate the program:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
The depth of the program was at just the right level.	The depth of the program was at just the right level. Strongly agree	The depth of the program was at just the right level. Agree	The depth of the program was at just the right level. Neutral	The depth of the program was at just the right level. Disagree	The depth of the program was at just the right level. Strongly disagree
The program was well organized.	The program was well organized. Strongly agree	The program was well organized. Agree	The program was well organized. Neutral	The program was well organized. Disagree	The program was well organized. Strongly disagree

Question Title

3. Did you perceive any bias during this presentation?

Yes

No

If Yes, please specify:

Question Title

4. Was at least 25% of total education time devoted to interactive learning?

Yes

No

Question Title

5. How would you rate the ease of use of this online format for this program?

Excellent

Good

Fair

Poor

Question Title

6. Which idea/concept/approach presented in this module would you like to apply to your practice?

Question Title

7. Which barriers do you anticipate when applying this concept?

Question Title

8. Please list any questions or items you would like to know more about regarding prescribing Paxlovid™ for COVID-19.

Question Title

9. Any other comments regarding the presentation or the format?